# US 11,897,940 B2 · Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,897,940 B2
- Document ID: US11897940B2
- Status: Granted
- Kind: B2
- Application number: 17/708,763
- Filed: 2022-03-30
- Published: 2022-11-03
- Granted: 2024-02-13
- Earliest claimed: 2016-12-27
- Assignees: The Rockefeller University; California Institute of Technology
- Applicants: The Rockefeller University; California Institute of Technology
- Inventors: Michel Nussenzweig; Natalia T. Freund; Pamela J. Bjorkman; Louise Scharf
- Web page: https://patentgrep.com/patent/US11897940B2

## CPC

- C07K 16/114: Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/18: for HIV
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.

## Claims

### Claim 1

An isolated nucleic acid encoding an anti-HIV antibody or antigen binding portion thereof comprising:
(i) a heavy chain variable region that comprises three heavy chain complementarity determining regions (CDRH 1, CDRH 2, and CDRH 3), wherein the CDRH 1, CDRH 2 and CDRH 3 comprise the respective sequences of SEQ ID NOs: 10-12, and
(ii) a light chain variable region that comprises three light chain complementarity determining regions (CDRL 1, CDRL 2 and CDRL 3), wherein the CDRL 1, CDRL 2 and CDRL 3 comprise the respective sequences of SEQ ID NOs: 14-16.

### Claim 2 (depends on 1)

A vector comprising the nucleic acid of claim 1.

### Claim 3 (depends on 2)

A cultured cell comprising the vector of claim 2.

### Claim 4 (depends on 1)

The isolated nucleic acid of claim 1, wherein the sequence encodes the anti-HIV-1 antibody or antigen binding portion thereof comprising one or both of (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9 and (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 13.

### Claim 5 (depends on 4)

The isolated nucleic acid of claim 4, wherein the anti-HIV-1 antibody or antigen binding portion thereof comprises both of the heavy chain variable region and the light chain variable region.

### Claim 6 (depends on 1)

The isolated nucleic acid of claim 1, wherein the anti-HIV-1 antibody is a scFv antibody.

### Claim 7 (depends on 2)

The vector of claim 2, wherein the vector is a plasmid, a phage vector, a viral vector, a cosmid, or an artificial chromosome.

### Claim 8 (depends on 7)

The vector of claim 7, wherein the viral vector is an adenoviral vector.

### Claim 9 (depends on 3)

The cultured cell of claim 3, wherein the cultured cell is a COS cell, a Chinese hamster ovary (CHO) cell, or a myeloma cell.